Untreated HCV in HIV/HCV-Coinfected US Population Despite an Abundance of Curative Therapies



Image: Second stateImage: Second s

R. Elion¹, K. Althoff², J. Eron³, J. Gillman⁴, R. Haubrich⁵, G. Huhn^{6,7}, S. Milligan⁸, A. Mills⁹, K. Mounzer^{10,11}, G. Moyle¹², J. Radtchenko⁸, S. Santiago¹³, P. Sax^{14,15}, D. Jayaweera¹⁶ ¹George Washington University School of Medicine, Washington DC, United States, ²John Hopkins University, Baltimore, United States, ³University, Baltimore, United States, ³University, Baltimore, United States, ⁴Prism Health, Dallas, ⁴Prism Heal ⁷The Ruth M. Rothstein CORE Center, Chicago, United States ⁸Trio Health, La Jolla, United States, ¹⁰University of Pennsylvania, Philadelphia Fight Community Health, Philadelphia, United States, ¹²Chelsea and Westminster Hospital, London, United Kingdom, ¹³Care Resource, Miami, United States, ¹⁴Brigham and Women's Hospital, Boston, United States, ¹⁵Harvard Medical School, Boston, United States, ¹⁶University of Miami, Miller School of Medicine-Division of Infectious Disease, Miami, United States

. BACKGROUND AND OBJECTIVE

Per AASLD-IDSA (www.hcvguidelines.org), treatment of hepatitis C should be prioritized in patients coinfected with HIV and HCV. This recommendation is based on a higher rate of HCV disease progression in this population, along with reported treatment responses comparable to HCV monoinfected patients.

Despite the availability of highly effective, well tolerated anti-HCV therapies, payers have created barriers to access in the HCV monoinfected population (J Viral Hepat 2016 23:447). However, in the HCV-HIV coinfected population, previous analyses suggest that payers do not influence access to DAAs, but rather lack of prescription accounts for most of the non-treated HCV (J Hep 2018 68: S261). Here we attempt to address the question of "How many patients remain untreated since the advent of curative DAAs?" by looking at coinfected populations from 2014 to 2018.

2. METHODS

EMR data for 3896 patients were collected from 10 large HIV treating clinics in the US. HIV infection was defined as positive HIV antibody lab result, at least 2 HIV viral loads >200 or 1 HIV viral load >500, HIV drug prescription and/or dispense, or HIV diagnosis (ICD9 0.42.x-0.44.x or ICD10 B20.x-B22.x, B24.x) and HCV infection was defined as ID9 0.070.41, 070.44, 070.51, 0.70.54, 0.70.7, 0.70.71, 070.54, V02.62; ICD10 B17.1, B17.10, B17.11, B18.2, B18.20, B19.2, B19.20, B19.21), HCV viral load >50, or HCV prescription or dispense.

Populations were assessed each year and for the entire time period and classified into one of the following groups: Treated or Cured (DAA prescription, dispense, or 2+ HCV RNA undetectable or <20 IU/ml), Lost to Follow Up (LTFU, no evidence of treatment or cure, without evidence of being in care as of OCT 2018), or Not treated (no evidence of treatment or cure, patient in database with evidence of HCV coinfection as of OCT 2018). [FIGURE 1] Trends were assessed by Cochran-Armitage test for trend in proportions. Differences between groups were assessed using chi-square with subsequent assessment of column proportions by Z tests with Bonferroni correction. Population characteristics were limited for this dataset, which prevented analyses evaluating the impact of payer on treatment status.

3. RESULTS

By year, the percentage of patients with active HCV that received treatment increased from 17% in 2014 to 23% (p<0.001) in the last period [FIGURE 3]. At the end of the observation period, 882 (23%) patients remained untreated, 1,210 (31%) were LTFU, and 1,804 (46%) were treated. [FIGURE 4]

Age and gender were available for 74% (2895/3896) patients. [TABLE 1] A significantly higher fraction of treated patients and lower fraction of LTFU were observed for males compared to females (p<0.001). The patient age group 50-64 had a higher fraction of treated patients compared to the <50 age group (p=0.023), though all other age comparisons were not significant.

Median (IQR) follow up was 32.2 (10.1-52.2) months. Median (IQR) follow up for untreated patients was 40.9 (11.3-54.1) months. For patients classified as LTFU, median (IQR) time from index to date of last care was 10.2 (1.8-27.9) months with observation of 39.0 (23.5-54.2) months. For treated patients, median (IQR) time from index to treatment was 14.2 (3.9-28.5) months.

4. CONCLUSION

In this cohort of coinfected patients, 23% remained untreated and 31% were lost to follow up. The data suggest that females and <50 year old patients had lower treatment rates. Median time to treatment was 4 months longer than median time of last care for patients lost to follow up, suggesting that more timely treatment and/or improved patient engagement are critical in care of the coinfected population. Despite the availability of highly effective, well tolerated DAAs [FIGURE 2], treatment of HCV in this population of coinfected patients was suboptimal.

FIGURE 1: PATIENT DISPOSITION FOR HCV TREATMENT



DISCLOSURES: Dr. Elion received grants from Gilead Sciences and Janssen. The University of North Carolina received funds for Speaker for Gilead Sciences and ViiV Healthcare, Gilead Sciences and Janssen. The University of North Carolina receives support as an investigator. Dr. Elion received funds for Speaking at symposia organized by Gilead and AbbVie Carolina received funds for Speaker for Gilead Sciences, and Janssen. The University of North Carolina receives support as an investigator. Dr. Althoff previously served on a Medical Advisory Board for Gilead Sciences, and Janssen. The University of North Carolina receives support as an investigator. Dr. Gilead Sciences and ViiV Healthcare, Gilead Sciences and Janssen. The University of North Carolina receives support as an investigator. Dr. Althoff previously served on a Medical Advisory Board for Gilead Sciences, and Janssen from which he receives support as an investigator. Dr. Gilead Sciences and Proteus, serves on the Advisory Board for Gilead Sciences, and Janssen. The University of North Carolina receives and Janssen. The University of Nort Search grants from ViiV Healthcare, Merck, Janssen, Bristol-Myers Squibb, and Sciences, Clinical care options, Simply speaking, Prime. Mounzer advisory Board for Epividian. Dr. Santiago serves on the speakers' bureau for ViiV Healthcare, Merck, Janssen, Bristol-Myers Squibb, and Sciences, He is on the speakers' bureau for ViiV Healthcare, Merck, Janssen, Bristol-Myers Squibb, and Sciences, Clinical care options, Simply speaking, Prime. Mounzer advisory Board for Epividian. Dr. Santiago serves on the speakers' bureau for ViiV Healthcare, Merck, Janssen, Bristol-Myers Squibb, and NIAID. Dr. Santiago serves on the speakers' bureau for ViiV Healthcare, Merck, Janssen, Gilead Sciences, He is on the advisory board for Epividian. Dr. Santiago serves on the medical Advisory Board for Epividian. Dr. Santiago serves on the speakers' bureau for ViiV Healthcare, Merck, Janssen, Gilead Sciences, He is on the speakers' bureau for ViiV Healthcare, Merck, Janssen, Gilead Sciences, He is on the advisory Board for Epividian. Dr. Santiago serves on the advisory Board for Epividian. Dr. Santiago serves for ViiV Healthcare, Merck, Janssen, Gilead Sciences, He is on the advisory Board for Epividian. Dr. Santiago serves for ViiV Healthcare, Merck, Janssen, Gilead Sciences, He is on the advisory Board for Epividian. Dr. Santiago serves for ViiV Healthcare, Merck, Janssen, Gilead Sciences, He is on the advisory Board for Epividian. Dr. Santiago serves for ViiV Healthcare, Merck, Janssen, Gilead Sciences, Clinical care options, Simply seakers, Breakers, Bre Dr. Moyle serves as a speaker and adviser to Merck, Gilead Sciences, Janssen, and ViiV Healthcare, Merck, Janssen, and Sax serve on Trio Health Sciences, ViiV Healthcare, Merck, Janssen. He received research grants from Gilead Sciences, Nerck, and ViiV Healthcare and Jansen. Drs. Althoff, Elion, Eron, Mounzer, Moyle, Santiago, Huhn, and Sax serve on Trio Health's Scientific Advisory Board. Sciences, ViiV Healthcare, Merck, Janssen. He received research grant support from Gilead Sciences, ViiV Healthcare, Merck, Janssen. Drs. Althoff, Elion, Eron, Mounzer, Moyle, Santiago, Huhn, and Sax serve on Trio Health's Scientific Advisory Board. Sciences, ViiV Healthcare, Merck, Janssen. Drs. Althoff, Elion, Eron, Mounzer, Moyle, Santiago, Huhn, and Sax serve on Trio Health's Scientific Advisory Board. Sciences, ViiV Healthcare, Merck, Janssen. Drs. Althoff, Elion, Eron, Mounzer, Moyle, Santiago, Huhn, and Sax serve on Trio Health's Scientific Advisory Board. Sciences, ViiV Healthcare, Merck, Janssen. Drs. Althoff, Elion, Eron, Mounzer, Moyle, Santiago, Huhn, and Sax serve on Trio Health's Scientific Advisory Board. Sciences, Merck, Janssen. Drs. Althoff, Elion, Eron, Mounzer, Moyle, Santiago, Huhn, and Sax serve on Trio Health's Scientific Advisory Board. Sciences, ViiV Healthcare, Merck, Janssen. Drs. Althoff, Elion, Eron, Mounzer, Moyle, Santiago, Huhn, and Sax serve on Trio Health's Scientific Advisory Board. Sciences, Merck, Janssen. Drs. Althoff, Elion, Eron, Mounzer, Moyle, Santiago, Huhn, and Sax serve on Trio Health's Sciences, Scie

FIGURE 2: AVAILABILITY OF DIRECT-ACTING ANTIVIRALS



FIGURE 3: PATIENTS WITH ACTIVE HCV AND PERCENTAGE TREATED IN EACH PERIOD



FIGURE 4: RUNNING TOTALS, HCV TREATMENT STATUS



TABLE 1: DISTRIBUTION BY FINAL TREATMENT STATUS BY GENDER AND AGE GROUP MALE (n=2142) TOTAL (N=2895) 28%_b 30% 50%_b 47% p<0.001 23%_a 23% 100% 100% 50-64 YEARS (n=1572) 65+ YEARS (n=398) TOTAL (n=2895) **29%**a 27%_a 30% 49%_b 48%_{a.b} 47% p=0.023 22%_a 23% 24%_a 100% 100% 100%

	FEMALE (n=753)
LTFU	36% _a
Treated	40%a
Untreated	24% _a
Total	100%
	18-49 YEARS (n=925)
LTFU	32% _a
Treated	43%a
Untreated	25%a
Total	100%
Feed subscript letter denotes a subsct of elegation estageries where actume as	

Prio Health

Each subscript letter denotes a subset of classification categories whose column proportions do not differ significantly from each other at the .05 level.

*Through October 2018